Latest / Cell & Gene: The Podcast

Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki
We love to hear from our listeners. Send us a message.
In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). Dr. Putzki walks us through the six-year development journey behind the STEER and STRENGTH Phase 3 programs. And we explore what the expanded age-range label means for patients who were previously left behind, why intrathecal, fixed-dose AAV delivery…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.